Innovation in bone healing and tissue repair

Didier Cowling - Founder and Chief Executive Officer

Didier Cowling co-founded Kuros in early 2002 and has been its CEO since then. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Joost de Bruijn - Chief Executive Officer of Xpand Biotechnology

Joost de Bruijn founded Xpand Biotechnology BV in 2005 and was Chief Executive Officer of Xpand ever since. He continues in this role after the acquisition by Kuros in early 2017. Dr. de Bruijn also holds the positions of Professor of Biomaterials at Queen Mary University of London, UK (since 2004) and Professor of Regenerative Medicine and Entrepreneurship at Twente University, the Netherlands (since 2011). In 2007, he founded Progentix Orthobiology that signed an exclusive development agreement with NuVasive in 2009 for a novel family of calcium phosphate synthetic bone substitutes. Prior to founding Xpand he was Research Director Bone at IsoTis for seven years, during which he specialized in bone tissue engineering technologies that were brought to clinical application. Dr. de Bruijn has more than 20 years experience in academia and the life science industry. He has published 165 papers in peer-reviewed journals, and is the inventor of 24 patent families. Dr. de Bruijn is scientific editor and reviewer for numerous international biomaterials, tissue engineering and regenerative medicine journals. He received his PhD from Leiden University in 1993.

Dr. Alistair Irvine - Chief Business Officer

Alistair joined Kuros as Director of Business Development in September 2006 following a period working as a technical and commercial consultant to the biotechnology industry. Prior to his work as a consultant he was Deputy Director of Research and Research Operations Manager at Innovata plc, where in addition to managing research programs in the fields of gene expression, cell culture, polymer science and oncology he also played a major role in business development. He has also held the positions of Head of Biology at ML Laboratories plc, Sub-divisional Head (Research) at Cobra Therapeutics Ltd, Group Leader (Immunotherapy) at Cobra Therapeutics Ltd and Senior Scientist with Therexsys Ltd. He has worked in the biotechnology/medtech industry for over 20 years. Dr. Irvine holds a PhD in Molecular Biology from the University of Sheffield and a BSc in Biochemistry from the University of Edinburgh.

Dr. Virginia Jamieson - Chief Medical Officer

Virginia worked for Kuros from 2005 until 2012 as Medical Director and then as Chief Medical Officer leading the clinical and regulatory functions.

She returned to Kuros Biosurgery in early 2016 as Chief Medical Officer overseeing the clinical development of the projects. Virginia has over 25 years of pharmaceutical industry experience covering all phases of development in a wide variety of therapeutic areas, following a career in Anaesthesia. She obtained a BSc in Medical Sciences and Medical Degree from Edinburgh University, a post-graduate fellowship in Anaesthesia from the Royal College of Anaesthetists in London and a Diploma in Pharmaceutical Medicine from the Royal College of Physicians in London.

Dr. Philippe Saudan - Chief Development Officer

Dr. Philippe Saudan was appointed Chief Development Officer in August 2016. He has spent more than 16 years in the pharmaceutical industry and held different management roles in research and development (R&D). Dr. Saudan has considerable experience in R&D and international project management of multidisciplinary programs. In his last position, he served as Chief Scientific Officer of Cytos Biotechnology, where he worked at the interface between pre-clinical research, manufacturing and development of several clinical projects. Since February 2016, Dr. Saudan was working as Head of Integration of Kuros Biosciences. In this position, he was closely involved in the different development programs in tissue repair and regeneration. Dr. Saudan holds a PhD in biology
from the University of Lausanne, Switzerland.

Dr. Jason Schense - Founder and Chief Technology Officer

Dr. Schense is currently working as Chief Technology Officer and is responsible for the ongoing operational activities. Prior to joining Kuros, Jason was employed as a Project Leader at Straumann Biologics where he spent a year developing novel synthetic matrices for enhanced osseous healing associated with dental implants. From 2000-2002, Jason was employed as a Project Scientist at Kuros Therapeutics, where he was responsible for synthetic and fibrin-based materials for both bone and wound repair. Jason received his PhD in 1999 from the California Institute of Technology working with Prof. Jeffrey Hubbell for the development of modified fibrin matrices for nerve regeneration. From this combined work, Jason has earned 19 publications, 10 conference presentations and is named as a co-inventor on all the patents in the field of delivery of growth factors from fibrin and modification of fibrin that Kuros has licensed for tissue regeneration from the ETHZ and Caltech. Jason earned his BSc from the Massachusetts Institute of Technology in Chemical Engineering.

Frank-Jan van der Velden - Head of Business Affairs and Finance of Xpand Biotechnology

Frank-Jan van der Velden was a co-founder of Xpand Biotechnology BV and acted as executive board member since then. He co-founded several other Dutch companies in the field of regenerative medicine, i.e. CellCoTec, Progentix Orthobiology and Materiomics. Before he co-founded Xpand, Mr. van der Velden was partner at management consultants Krüger & Partners for 10 years. Prior to that, he acted as director of Quote Media Holding. Currently, Mr. van der Velden is a board member of RiverDiagnostics International, member of the executive board of Materiomics and chairman of the supervisory board of TIIN Techfund III BV, a venture capital fund for technology start-ups. Mr van der Velden is a graduate of Erasmus University Rotterdam School of Management.

Harry Welten - Chief Financial Officer

Harry Welten, MBA, serves as Board member of the Company. From June 2010 to January 2016 he served as Executive Vice President and Chief Financial Officer of Cytos. He has more than 20 years of international senior executive experience, fourteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the Chief Financial Officer at Nitec Pharma AG in Reinach which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the Chief Financial Officer at Arpida AG which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a Director at UBS Warburg in New York following various senior positions within the UBS Group. Before joining UBS, he was with ABB and DaimlerChrysler. He is a member of the Board of Directors of Anokion, BiognoSYS AG, ProteoMediX, Horizon Pharma AG as well as of BioSupport AG. Furthermore, he is a member of the foundation council of HBM Fondation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York.

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Management

Didier Cowling
Founder and Chief Executive Officer

Didier Cowling co-founded Kuros in early 2002 and has been its CEO since then. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Joost de Bruijn
Chief Executive Officer of Xpand Biotechnology

Joost de Bruijn founded Xpand Biotechnology BV in 2005 and was Chief Executive Officer of Xpand ever since. He continues in this role after the acquisition by Kuros in early 2017. Dr. de Bruijn also holds the positions of Professor of Biomaterials at Queen Mary University of London, UK (since 2004) and Professor of Regenerative Medicine and Entrepreneurship at Twente University, the Netherlands (since 2011). In 2007, he founded Progentix Orthobiology that signed an exclusive development agreement with NuVasive in 2009 for a novel family of calcium phosphate synthetic bone substitutes. Prior to founding Xpand he was Research Director Bone at IsoTis for seven years, during which he specialized in bone tissue engineering technologies that were brought to clinical application. Dr. de Bruijn has more than 20 years experience in academia and the life science industry. He has published 165 papers in peer-reviewed journals, and is the inventor of 24 patent families. Dr. de Bruijn is scientific editor and reviewer for numerous international biomaterials, tissue engineering and regenerative medicine journals. He received his PhD from Leiden University in 1993.

Dr. Alistair Irvine
Chief Business Officer

Alistair joined Kuros as Director of Business Development in September 2006 following a period working as a technical and commercial consultant to the biotechnology industry. Prior to his work as a consultant he was Deputy Director of Research and Research Operations Manager at Innovata plc, where in addition to managing research programs in the fields of gene expression, cell culture, polymer science and oncology he also played a major role in business development. He has also held the positions of Head of Biology at ML Laboratories plc, Sub-divisional Head (Research) at Cobra Therapeutics Ltd, Group Leader (Immunotherapy) at Cobra Therapeutics Ltd and Senior Scientist with Therexsys Ltd. He has worked in the biotechnology/medtech industry for over 20 years. Dr. Irvine holds a PhD in Molecular Biology from the University of Sheffield and a BSc in Biochemistry from the University of Edinburgh.

Dr. Virginia Jamieson
Chief Medical Officer

Virginia worked for Kuros from 2005 until 2012 as Medical Director and then as Chief Medical Officer leading the clinical and regulatory functions.

She returned to Kuros Biosurgery in early 2016 as Chief Medical Officer overseeing the clinical development of the projects. Virginia has over 25 years of pharmaceutical industry experience covering all phases of development in a wide variety of therapeutic areas, following a career in Anaesthesia. She obtained a BSc in Medical Sciences and Medical Degree from Edinburgh University, a post-graduate fellowship in Anaesthesia from the Royal College of Anaesthetists in London and a Diploma in Pharmaceutical Medicine from the Royal College of Physicians in London.

Dr. Philippe Saudan
Chief Development Officer

Dr. Philippe Saudan was appointed Chief Development Officer in August 2016. He has spent more than 16 years in the pharmaceutical industry and held different management roles in research and development (R&D). Dr. Saudan has considerable experience in R&D and international project management of multidisciplinary programs. In his last position, he served as Chief Scientific Officer of Cytos Biotechnology, where he worked at the interface between pre-clinical research, manufacturing and development of several clinical projects. Since February 2016, Dr. Saudan was working as Head of Integration of Kuros Biosciences. In this position, he was closely involved in the different development programs in tissue repair and regeneration. Dr. Saudan holds a PhD in biology
from the University of Lausanne, Switzerland.

Dr. Jason Schense
Founder and Chief Technology Officer

Dr. Schense is currently working as Chief Technology Officer and is responsible for the ongoing operational activities. Prior to joining Kuros, Jason was employed as a Project Leader at Straumann Biologics where he spent a year developing novel synthetic matrices for enhanced osseous healing associated with dental implants. From 2000-2002, Jason was employed as a Project Scientist at Kuros Therapeutics, where he was responsible for synthetic and fibrin-based materials for both bone and wound repair. Jason received his PhD in 1999 from the California Institute of Technology working with Prof. Jeffrey Hubbell for the development of modified fibrin matrices for nerve regeneration. From this combined work, Jason has earned 19 publications, 10 conference presentations and is named as a co-inventor on all the patents in the field of delivery of growth factors from fibrin and modification of fibrin that Kuros has licensed for tissue regeneration from the ETHZ and Caltech. Jason earned his BSc from the Massachusetts Institute of Technology in Chemical Engineering.

Frank-Jan van der Velden
Head of Business Affairs and Finance of Xpand Biotechnology

Frank-Jan van der Velden was a co-founder of Xpand Biotechnology BV and acted as executive board member since then. He co-founded several other Dutch companies in the field of regenerative medicine, i.e. CellCoTec, Progentix Orthobiology and Materiomics. Before he co-founded Xpand, Mr. van der Velden was partner at management consultants Krüger & Partners for 10 years. Prior to that, he acted as director of Quote Media Holding. Currently, Mr. van der Velden is a board member of RiverDiagnostics International, member of the executive board of Materiomics and chairman of the supervisory board of TIIN Techfund III BV, a venture capital fund for technology start-ups. Mr van der Velden is a graduate of Erasmus University Rotterdam School of Management.

Harry Welten
Chief Financial Officer

Harry Welten, MBA, serves as Board member of the Company. From June 2010 to January 2016 he served as Executive Vice President and Chief Financial Officer of Cytos. He has more than 20 years of international senior executive experience, fourteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the Chief Financial Officer at Nitec Pharma AG in Reinach which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the Chief Financial Officer at Arpida AG which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a Director at UBS Warburg in New York following various senior positions within the UBS Group. Before joining UBS, he was with ABB and DaimlerChrysler. He is a member of the Board of Directors of Anokion, BiognoSYS AG, ProteoMediX, Horizon Pharma AG as well as of BioSupport AG. Furthermore, he is a member of the foundation council of HBM Fondation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York.